BR112022007489A2 - Forma amorfa de um receptor c5a de componente do complemento - Google Patents
Forma amorfa de um receptor c5a de componente do complementoInfo
- Publication number
- BR112022007489A2 BR112022007489A2 BR112022007489A BR112022007489A BR112022007489A2 BR 112022007489 A2 BR112022007489 A2 BR 112022007489A2 BR 112022007489 A BR112022007489 A BR 112022007489A BR 112022007489 A BR112022007489 A BR 112022007489A BR 112022007489 A2 BR112022007489 A2 BR 112022007489A2
- Authority
- BR
- Brazil
- Prior art keywords
- amorphous form
- receptor
- complement component
- compound
- complement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Secondary Cells (AREA)
- Soft Magnetic Materials (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932644P | 2019-11-08 | 2019-11-08 | |
| PCT/US2020/059280 WO2021092286A1 (en) | 2019-11-08 | 2020-11-06 | Amorphous form of a complement component c5a receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022007489A2 true BR112022007489A2 (pt) | 2022-07-12 |
Family
ID=75846408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022007489A BR112022007489A2 (pt) | 2019-11-08 | 2020-11-06 | Forma amorfa de um receptor c5a de componente do complemento |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11603356B2 (https=) |
| EP (1) | EP4054576A4 (https=) |
| JP (2) | JP2023501789A (https=) |
| KR (1) | KR20220098754A (https=) |
| CN (1) | CN114641288A (https=) |
| AU (1) | AU2020378397A1 (https=) |
| BR (1) | BR112022007489A2 (https=) |
| CA (1) | CA3155542A1 (https=) |
| CL (1) | CL2022001172A1 (https=) |
| IL (1) | IL292383A (https=) |
| MX (1) | MX2022005406A (https=) |
| WO (1) | WO2021092286A1 (https=) |
| ZA (1) | ZA202305624B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114867473A (zh) | 2019-11-08 | 2022-08-05 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
| US11603356B2 (en) | 2019-11-08 | 2023-03-14 | Chemocentryx, Inc. | Amorphous form of a complement component C5a receptor |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
| EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
| WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
| US20250333381A1 (en) | 2024-04-26 | 2025-10-30 | Amgen Inc. | Solid state forms |
| US20260027049A1 (en) | 2024-07-23 | 2026-01-29 | Amgen Inc. | Avacopan formulations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4996467B2 (ja) * | 2004-09-27 | 2012-08-08 | アカディア ファーマシューティカルズ インコーポレイテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成 |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| RS54998B1 (sr) | 2008-12-22 | 2016-11-30 | Chemocentryx Inc | Antagonisti c5ar |
| RS56332B1 (sr) | 2010-06-24 | 2017-12-29 | Chemocentryx Inc | Antagonisti c5ar |
| DK3200791T3 (da) * | 2014-09-29 | 2020-05-25 | Chemocentryx Inc | Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister |
| CA3078732A1 (en) | 2017-10-31 | 2019-05-09 | Chemocentryx, Inc. | C5ar inhibitor reduction of urinary scd163 |
| US11191756B2 (en) | 2018-06-07 | 2021-12-07 | Chemocentryx, Inc. | Dosing and effect of C5a antagonist with ANCA-associated vasculitis |
| WO2020112961A1 (en) | 2018-11-30 | 2020-06-04 | Chemocentryx, Inc. | Capsule formulations |
| IL312955B1 (en) | 2019-03-11 | 2026-01-01 | Inflarx Gmbh | Fused piperidinyl bicyclic compounds and related compounds as C5a receptor modulators |
| CN114867473A (zh) | 2019-11-08 | 2022-08-05 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
| US11603356B2 (en) | 2019-11-08 | 2023-03-14 | Chemocentryx, Inc. | Amorphous form of a complement component C5a receptor |
| JP2022554019A (ja) | 2019-11-08 | 2022-12-27 | ケモセントリックス，インコーポレイティド | 補体成分Ｃ５ａ受容体の遊離塩基結晶形態 |
| WO2022078269A1 (zh) | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
-
2020
- 2020-11-06 US US17/091,001 patent/US11603356B2/en active Active
- 2020-11-06 CN CN202080077440.0A patent/CN114641288A/zh active Pending
- 2020-11-06 JP JP2022525877A patent/JP2023501789A/ja active Pending
- 2020-11-06 MX MX2022005406A patent/MX2022005406A/es unknown
- 2020-11-06 CA CA3155542A patent/CA3155542A1/en active Pending
- 2020-11-06 BR BR112022007489A patent/BR112022007489A2/pt unknown
- 2020-11-06 IL IL292383A patent/IL292383A/en unknown
- 2020-11-06 KR KR1020227018914A patent/KR20220098754A/ko not_active Ceased
- 2020-11-06 AU AU2020378397A patent/AU2020378397A1/en active Pending
- 2020-11-06 WO PCT/US2020/059280 patent/WO2021092286A1/en not_active Ceased
- 2020-11-06 EP EP20883775.7A patent/EP4054576A4/en active Pending
-
2022
- 2022-05-04 CL CL2022001172A patent/CL2022001172A1/es unknown
-
2023
- 2023-05-25 ZA ZA2023/05624A patent/ZA202305624B/en unknown
-
2025
- 2025-10-09 JP JP2025171004A patent/JP2026016449A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202128622A (zh) | 2021-08-01 |
| US20210139426A1 (en) | 2021-05-13 |
| US11603356B2 (en) | 2023-03-14 |
| ZA202305624B (en) | 2023-12-20 |
| CL2022001172A1 (es) | 2023-02-17 |
| KR20220098754A (ko) | 2022-07-12 |
| MX2022005406A (es) | 2022-05-24 |
| WO2021092286A1 (en) | 2021-05-14 |
| JP2023501789A (ja) | 2023-01-19 |
| EP4054576A4 (en) | 2023-12-13 |
| JP2026016449A (ja) | 2026-02-03 |
| CN114641288A (zh) | 2022-06-17 |
| AU2020378397A1 (en) | 2022-06-23 |
| EP4054576A1 (en) | 2022-09-14 |
| IL292383A (en) | 2022-06-01 |
| CA3155542A1 (en) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022007489A2 (pt) | Forma amorfa de um receptor c5a de componente do complemento | |
| BR112022007488A2 (pt) | Forma cristalina de base livre de um receptor c5a de componente do complemento | |
| MX2018010983A (es) | Derivado de 3-desoxi y composiciones farmaceuticas del mismo. | |
| PH12020551501A1 (en) | Oxadiazole transient receptor potential channel inhibitors | |
| HK1257569A1 (zh) | 磺醯脲和相关化合物及其用途 | |
| EP4609866A3 (en) | Oxysterols and methods of use thereof | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| EP4599887A8 (en) | Oxysterols and methods of use thereof | |
| EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
| WO2019224790A3 (en) | Prodrugs of fulvestrant | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| BR112017016378A2 (pt) | composições da pró-droga de fumarato de monometila | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| JOP20200191A1 (ar) | مشتقات أوكسادايازولو بيريدين بها استبدال بسيكليل غير متجانسة للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat) | |
| BR112022008183A2 (pt) | Formas de sal de um receptor de c5a de componente do complemento | |
| CO2022009260A2 (es) | Composiciones farmacéuticas oftálmicas | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
| ZA202001295B (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
| NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
| PH12020550549A1 (en) | Compositions for preventing or treating lupus | |
| WO2019151965A3 (en) | Solid oral pharmaceutical compositions comprising apixaban | |
| PH12020551620A1 (en) | Compositions for preventing or treating dry eye |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |